Stockscreener 앱 받기
36.35
5.89%
2.18
전일 마감가:
$34.17
열려 있는:
$35.25
하루 거래량:
2.14M
Relative Volume:
0.97
시가총액:
$6.04B
수익:
$1.48B
순이익/손실:
$241.66M
주가수익비율:
25.38
EPS:
1.4325
순현금흐름:
$480.33M
1주 성능:
+5.98%
1개월 성능:
+3.85%
6개월 성능:
+16.45%
1년 성능:
+15.23%
1일 변동 폭
$34.07
$36.55
1주일 범위
$33.12
$36.55
52주 변동 폭
$25.16
$36.55
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, ZTS, TEVA, HLN, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
36.34 | 5.68B | 1.48B | 241.66M | 480.33M | 1.4325 |
TAK
Takeda Pharmaceutical Co Adr
|
16.54 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.62 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.85 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.195 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
571.57 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-11-11 | 개시 | Truist | Buy |
| 2025-09-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Stifel raises Alkermes stock price target on orexin pipeline progress - Investing.com
Alkermes Q1 2026 slides: Avadel deal drives revenue beat - Investing.com
Alkermes plc Reports First Quarter 2026 Financial Results - BioSpace
ALKS: Q1 2026 delivered robust sales growth, expanded sleep medicine presence, and advanced orexin pipeline - TradingView
Earnings call transcript: Alkermes Q1 2026 results beat expectations, stock rises - Investing.com
Alkermes Plc reports results for the quarter ended March 31Earnings Summary - TradingView
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo! Finance Canada
Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss - ChartMill
Alkermes rises as quarterly loss narrows, tops estimates - Investing.com
(ALKS) Alkermes Expects 2026 Revenue Range $1.73B$1.84B, vs. FactSet Est of $1.80B - marketscreener.com
Earnings Flash (ALKS) Alkermes Posts Q1 Net Loss $0.40 a Share, vs. FactSet Est of $0.58 Loss - marketscreener.com
Alkermes reports Q1 2026: Revenues $392.9M, GAAP loss $66.5M, Adjusted EBITDA $80.3M - TradingView
Alkermes: Q1 Earnings Snapshot - KING5.com
Avadel deal drives Alkermes (NASDAQ: ALKS) Q1 growth and 2026 EBITDA upgrade - Stock Titan
Alkermes Q1 2026 earnings preview - MSN
Alkermes earnings on deck: Can Lumryz offset Avadel deal costs? By Investing.com - Investing.com Nigeria
Alkermes earnings on deck: Can Lumryz offset Avadel deal costs? - Investing.com
ALKS SEC FilingsAlkermes Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Avadel Pharmaceuticals 2025 Financial Results, Alkermes Acquisition, and LUMRYZ Commercial Highlights - Minichart
Alkermes (NASDAQ:ALKS) EVP Sells $300,600.00 in Stock - MarketBeat
Alkermes (NASDAQ: ALKS) EVP exercises 5,000 options and sells 9,000 shares - Stock Titan
Alkermes (NASDAQ: ALKS) details Avadel buyout terms and 2025 results - Stock Titan
Alkermes plc (NASDAQ: ALKS) insider sales, option exercise and PSU vesting noted - Stock Titan
Behavioral Patterns of ALKS and Institutional Flows - Stock Traders Daily
Alkermes plc $ALKS Shares Bought by Pictet Asset Management Holding SA - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $5.44 Million Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes (NASDAQ:ALKS) Rating Increased to Hold at Zacks Research - MarketBeat
Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential - ChartMill
Do options traders know something about Alkermes stock we don't? - MSN
Vanguard Portfolio Management (NASDAQ: ALKS) reports 9.65M shares beneficially owned - Stock Titan
Alkermes (ALKS) Expected to Announce Earnings on Tuesday - MarketBeat
Wall Street Analysts Believe Alkermes (ALKS) Could Rally 29.14%: Here's is How to Trade - Zacks Investment Research
Vanguard holds 8.68M shares in Alkermes (NASDAQ: ALKS) via Schedule 13G - Stock Titan
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline - Yahoo Finance
Alkermes plc Announces CEO Succession Plan - Quantisnow
Alkermes announces CEO succession plan - MSN
Are options traders betting on a big move in Alkermes stock? - MSN
Wells Fargo Maintains Alkermes (ALKS) Overweight Recommendation - MSN
Alkermes plc (ALKS) Investor Outlook: Analyzing a 32.80% Upside Potential Amidst a Challenging Year - DirectorsTalk Interviews
Avadel Stock Rises After Acquisition Offer By Alkermes - MSN
Did New Alixorexton Data and LYBALVI Outcomes Just Shift Alkermes' (ALKS) Neuroscience Investment Narrative? - Yahoo Finance
ALKS stock surges 15% on Lilly-Centessa buyout igniting sleep pipeline hopes - MSN
Abacus FCF Advisors LLC Makes New Investment in Alkermes plc $ALKS - MarketBeat
Alkermes plc (NASDAQ:ALKS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Alkermes (NASDAQ:ALKS) Share Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Do Options Traders Know Something About Alkermes Stock We Don't? - TradingView
Alkermes to Report First Quarter Financial Results on May 5, 2026 - 富途牛牛
Is It Too Late To Consider Alkermes (ALKS) After Its Recent 19% Share Price Jump? - simplywall.st
Alkermes (ALKS) nears 52-week high on increasing orexin receptor market interest - MSN
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
2.82%
자본화:
|
볼륨(24시간):